On September 16, 2019 Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported that Dr. Mahesh Patel, Chairman, President and CEO, will participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma, Rare Disease & Gene Therapy, being held September 23-24, 2019 in New York City (Press release, Lipocine, SEP 16, 2019, View Source;co-fall-summit-focused-on-specialty-pharma-rare-disease–gene-therapy-300918042.html [SID1234539571]). Lipocine will be available to meet with investors in a one on one format. There will be no webcast presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!